Publique en esta revista
Información de la revista
Vol. 4. Núm. S1.
Monográfico: Enfermedades sistémicas autoinmunitarias
Páginas 40-44 (Marzo 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 4. Núm. S1.
Monográfico: Enfermedades sistémicas autoinmunitarias
Páginas 40-44 (Marzo 2008)
Enfermedades sistémicas autoinmunitarias
Acceso a texto completo
Miopatías inflamatorias. Nuevos conceptos
Inflammatory Myopathies. New Concepts
Visitas
...
Francisco Javier López Longo??
Autor para correspondencia
fjlopezlongo@hotmail.com

Correspondencia: Dr. F.J. López Longo. Servicio de Reumatología. Hospital General Universitario Gregorio Marañón. Dr. Esquerdo, 46. 28007 Madrid. España.
Servicio de Reumatología. Hospital General Universitario Gregorio Marañón. Universidad Complutense. Madrid. España
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

Las miopatías son enfermedades caracterizadas por afectar de forma primaria al músculo esquelético. En general cursan con debilidad, dolor, contractura, calambres, rigidez o fatiga. Pueden ser hereditarias, como las miopatías distróficas, congénitas, miotónicas, metabólicas y miasténicas, o adquiridas. Entre estas últimas se incluyen las miopatías inflamatorias idiopáticas (MII), tóxicas, endocrinas o infecciosas y la miastenia gravis. Actualmente, se acepta que existe un solapamiento clínico e histopatológico considerable entre algunas distrofias musculares y algunas MII. Sin embargo, el perfil molecular del músculo es diferente y característico en cada miopatía, por lo que el estudio de los patrones de expresión de genes en el músculo puede ser útil en su diagnóstico diferencial, incluso en las MII.

Palabras clave:
Miopatía
Polimiositis
Dermatomiositis
Antisintetasas

Myopathies are diseases characterized by the primary affection of skeletal muscle. In general they present with muscle weakness, pain, contracture, paresthesias, rigidity, or fatigue. They can be hereditary, such as muscle dystrophies, congenital, myotonic, metabolic, and myasthenic, or acquired. Among the latter ones we include idiopathic inflammatory myopathies (IIM), toxic, endocrine, or infectious myopathies and myasthenia gravis.

There is a current acceptance of considerable clinical and histopathological overlap among some muscle dystrophies and some IIM. However, the molecular profile is different and characteristic in each myopathy and the study into the patterns of expression of genes in the muscle can be useful in their differential diagnosis, including that of IIM.

Key words:
Myopathy
Polimyositis
Dermatomyositis
Antisynthetases
El Texto completo está disponible en PDF
Bibliografía
[1.]
Y. Troyanov, I.N. Targoff, J.L. Tremblay, J.R. Goulet, Y. Raymond, J.L. Senecal.
Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.
Medicine (Baltimore), 84 (2005), pp. 231-249
[2.]
G.J. Hengstman, W.T. Vree Egberts, H.P. Seelig, et al.
Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen.
Ann Rheum Dis, 65 (2006), pp. 242-245
[3.]
A. Ponyi, T. Constantin, M. Garami, C. András, B. Tállai, A. Váncsa, et al.
Cancer-associated myositis: clinical features and prognostic signs.
Ann N Y Acad Sci, 1051 (2005), pp. 64-71
[4.]
H. Chinoy, N. Fertig, C.V. Oddis, W.E. Ollier, R.G. Cooper.
The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis.
Ann Rheum Dis, (2007),
[5.]
R. Brouwer, G.J. Hengstman, W. Vree Egberts, H. Ehrfeld, B. Bozic, A. Ghirardello, et al.
Autoantibody profiles in the sera of European patients with myositis.
Ann Rheum Dis, 60 (2001), pp. 116-123
[6.]
A. Ghirardello, S. Zampieri, E. Tarricone, L. Iaccarino, R. Bendo, C. Briani, et al.
Clinical implications of autoantibody screening in patients with autoimmune myositis.
Autoimmunity, 39 (2006), pp. 217-221
[7.]
C. Sordet, J. Goetz, J. Sibilia.
Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease.
Joint Bone Spine, 73 (2006), pp. 646-654
[8.]
G.J. Hengstman, R. Brouwer, W.T. Egberts, H.P. Seelig, P.J. Jongen, W.J. Van Venrooij, et al.
Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.
J Neurol, 249 (2002), pp. 69-75
[9.]
G.J. Hengstman, H.J. Ter Laak, W.T. Vree Egberts, I.E. Lundberg, H.M. Moutsopoulos, J. Vencovsky, et al.
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.
Ann Rheum Dis, 65 (2006), pp. 1635-1638
[10.]
I.N. Targoff, G. Mamyrova, E.P. Trieu, O. Perurena, B. Koneru, T.P. O’Hanlon, et al.
A novel autoantibody to a 155-kd protein is associated with dermatomyositis.
Arthritis Rheum, 54 (2006), pp. 3682-3689
[11.]
K. Kaji, M. Fujimoto, M. Hasegawa, M. Kondo, Y. Saito, K. Komura, et al.
Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy.
Rheumatology (Oxford), 46 (2007), pp. 25-28
[12.]
S. Sato, M. Hirakata, M. Kuwana, A. Suwa, S. Inada, T. Mimori, et al.
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis.
Arthritis Rheum, 52 (2005), pp. 1571-1576
[13.]
G. Schilders, W.V. Egberts, R. Raijmakers, G.J. Pruijn.
C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
Arthritis Rheum, 56 (2007), pp. 2449-2454
[14.]
H. Alexanderson, M. Dastmalchi, M. Esbjörnsson-Liljedahl, C.H. Opava, I.E. Lundberg.
Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis.
Arthritis Rheum, 57 (2007), pp. 768-777
[15.]
Y.L. Chung, H. Alexanderson, N. Pipitone, C. Morrison, M. Dastmalchi, C. Ståhl-Hallengren, et al.
Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial.
Arthritis Rheum, 57 (2007), pp. 694-702
[16.]
K. Ikezoe, S. Ohshima, M. Osoegawa, M. Tanaka, K. Ogawa, K. Nagata, et al.
Expression of granulysin in polymyositis and inclusion-body myositis.
J Neurol Neurosurg Psychiatry, 77 (2006), pp. 1187-1190
[17.]
M.C. Dalakas.
The role of high-dose immune globulin intravenous in the treatment of dermatomyositis.
Int Immunopharmacol, 6 (2006), pp. 550-556
[18.]
P. Efthimiou, S. Schwartzman, L.J. Kagen.
Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.
Ann Rheum Dis, 65 (2006), pp. 1233-1236
[19.]
S. Dold, M.E. Justiniano, J. Marquez, L.R. Espinoza.
Treatment of early and refractory dermatomyositis with infliximab: a report of two cases.
Clin Rheumatol, 26 (2007), pp. 1186-1188
[20.]
F. Iannone, C. Scioscia, P.C. Falappone, M. Covelli, G. Lapadula.
Use of etanercept in the treatment of dermatomyositis: a case series.
J Rheumatol, 33 (2006), pp. 1802-1804
[21.]
L. Brulhart, J.M. Waldburger, C. Gabay.
Rituximab in the treatment of antisynthetase syndrome.
Ann Rheum Dis, 65 (2006), pp. 974-975
[22.]
T.D. Levine.
Rituximab in the treatment of dermatomyositis: an open-label pilot study.
Arthritis Rheum, 52 (2005), pp. 601-607
[23.]
E.H. Noss, D.L. Hausner-Sypek, M.E. Weinblatt.
Rituximab as therapy for refractory polymyositis and dermatomyositis.
J Rheumatol, 33 (2006), pp. 1021-1026
[24.]
Y. Yamasaki, H. Yamada, M. Yamasaki, M. Ohkubo, K. Azuma, S. Matsuoka, et al.
Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis.
Rheumatology (Oxford), 46 (2007), pp. 124-130
[25.]
I. García-Doval, M. Cruces.
Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients.
Dermatology, 209 (2004), pp. 247-248
[26.]
I.M. Bronner, M.F. Van der Meulen, M. De Visser, S. Kalmijn, W.J. Van Venrooij, A.E. Voskuyl, et al.
Long-term outcome in polymyositis and dermatomyositis.
Ann Rheum Dis, 65 (2006), pp. 1456-1461
[27.]
A. Ponyi, G. Borgulya, T. Constantin, A. Vancsa, L. Gergely, K. Danko.
Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis.
Rheumatology (Oxford), 44 (2005), pp. 83-88
[28.]
A. Airio, H. Kautiainen, M. Hakala.
Prognosis and mortality of polymyositis and dermatomyositis patients.
Clin Rheumatol, 25 (2006), pp. 234-239
[29.]
C. Torres, R. Belmonte, L. Carmona, F.J. Gómez-Reino, M. Galindo, B. Ramos, et al.
Survival, mortality and causes of death in inflammatory myopathies.
Autoimmunity, 39 (2006), pp. 205-215
Copyright © 2008. Elsevier España S.L. Barcelona
Idiomas
Reumatología Clínica

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?